[Research advances of anti-CD40 monoclonal antibody].

Title[Research advances of anti-CD40 monoclonal antibody].
Publication TypeJournal Article
Year of Publication2013
AuthorsLuo L-L, Zhang Y, Hou C-M, Qiao C-X, Li Y
JournalZhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology
Volume21
Issue2
Pagination508-12
Date Published2013 Apr
Abstract

CD40 and its receptor CD40L are a very important pair of co-stimulating molecule in immune response, which have extensive biological effects. After stimulating CD40 signal, it can exert corresponding function through MAPK (JNK, ERK, p38) pathway, PI3K cascade, as well as NF-κB and STAT. The CD40 signal is closely related to tumor immunity, this moleculer has already become targeted-molecule for cancer treatment. Recently, there have been many anti-CD40 monoclonal antibodies displaying good anti-cancer effect, among which CHIR-12.12, SGN-40 and CP-870, 893 developed rapidly and successively have entered clinical research stage. This review focuses the status of anti-CD40 monoclonal antibody, including distribution of CD40, physiological function of CD40, CD40 and tumor immunity, anti-CD40 monoclonal antibodies and so on.

DOI10.1155/2013/267285
Alternate JournalZhongguo Shi Yan Xue Ye Xue Za Zhi